Immunohistochemical staining of normal, non-alcoholic steatohepatitis, and non-alcoholic steatohepatitis cirrhosis liver tissue with a galectin-3 antibody. A: Normal liver: In the normal liver, immunoreactive galectin-3 is present in epithelial cells of all large and small bile ducts and in periportal ductules; B: Non-alcoholic steatohepatitis (NASH) liver: In livers with inflammatory disease, staining appears in activated macrophages both in the parenchyma and in the portal tracts as well as in lymphoid germinal centers when present in chronic hepatitis. Notably there is no galectin-3 positivity in hepatocytes in pre-cirrhotic inflammatory disease, even in the presence of ballooning degeneration, Mallory-Denk bodies or features of apoptosis; C: NASH cirrhosis: Galectin-3 appears in hepatocytes and can be focal or widespread with both cytoplasmic and nuclear activity. <br/ ><br/ >Kram M. Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World J Hepatol 2023; 15(2): 201-207 [PMID: 36926236 DOI: 10.4254/wjh.v15.i2.201]

Are you saying the KOLs are making things up at the top liver conference? I'll take their expertise over some anonymous stock board poster.

Geeez, you are bringing up a frivolous allegation from more than 10 years ago. Wow, you are grasping for straws trying to come up with something negative against this company. A judge tossed out the frivolous lawsuit back then. The author of this hit piece Adam F. has a political agenda against the Chairman of the company. Wow, you shorts are so desperate for any dirt to find, anything even if it is nothing.

I think we will see big pharma taking increasing interest in galectin-3 as a therapeutic target. It could become the next hot pharma target after GLP-1 agonists.